|
|
|
Click here to download
|
About The Pharmaceutical Strategy Series
The Pharmaceutical Strategy Series produces executive-level conferences that
bring together R&D leaders and corporate executives to assess business
opportunities, enhance corporate value, and forecast the economic and regulatory landscape within the rapidly changing pharmaceutical &
biotechnology industries.
PSS conferences are uniquely designed to maximize peer-to-peer networking
and idea sharing. Conference topics are chosen based on attendee feedback and advice given by the PSS Advisory
Board, which is comprised of decision-makers at most of the world's leading
pharmaceutical companies. Presentations in each Executive Conference will
give you the ideas, information, and resources you need to make faster and
smarter decisions.
The Pharmaceutical Strategy Series is a division of Cambridge Healthtech
Institute. |
Second Annual
Global
R&D Congress
Strategic Planning for Discovery, Development and Clinical Operations in China, India and other Emerging Regions
May
29-30, 2008 • The Ritz-Carlton • Washington, D.C.
Program
| Register
- Understanding IP barriers and trends when planning a global strategy in India, China and other markets
- Best approaches to outsourcing, in-licensing, out-licensing, and risk sharing partnerships
- Examining the regulatory landscape of Asia, Eastern Europe and Latin America
- Clarifying the business, regulatory and research environment for drug discovery, drug development and clinical research
- Managing complicated and long-distance collaborative third-party relationships
- Overcoming the logistical challenges of transferring technology and data, and training staff
- Embracing and integrating the opportunities of emerging regions through innovative strategies and flexible approaches
- Sourcing the globe for the best in discovery and development services and partners
- Strategic planning for clinical development operations
|
|
|
|
Effective
Alliance Management
June 4-5, 2008 • Philadelphia, PA
Program
| Register
| Download
Brochure
|
|
|
|
Managing
Projects & Resources
June 5-6, 2008 • Philadelphia, PA
Program
| Register
| Download
Brochure
|
|
|
|
Third Annual
Drug Development China
Strategies for Launching Discovery and Development Activities
September 17-18, 2008 • The Fairmont • San Francisco, CA
Program
| Register
-
Integrating Intellectual Property Management and Regulatory Compliance
-
Understanding Key Drivers so to Best Leverage Emerging Markets to Develop Novel Drugs
-
In-Licensing, Out-Licensing, and Risk Sharing: The China Landscape for Partnership Deals
-
Opportunities for Drug Discovery in China (Chemistry, Biology, Integrated Projects)
-
Why Conducting Preclinical Work in China is the Future
-
Strategic Planning for Clinical Development Operations in China
|
|
|
|
Post-Approval
Drug Safety Strategies
November 12-14, 2008 • Arlington, VA
Program
| Register
| Download
Brochure
|
|
|
Strategic
Resource Management
November 17-18, 2008 • Philadelphia, PA
Program
| Register
| Download
Brochure
|
|
|
|
Portfolio
Management
November 18-19, 2008 • Philadelphia, PA
Program
| Register
| Download
Brochure
|
|
|
|
|
The role of the Advisory Board is to assist CHI in
identifying those issues which are seminal to decision-making in today's
challenging world of drug development with the expressed intention of
creating a forum for dialogue, constructive debate, and shared learning
within the industry."
Richard M.
Bayney, Ph.D.,
Vice President, Decision Analysis & Portfolio Management, PRD,
Johnson & Johnson
|
|
|
For partnering and sponsorship information, please contact:
|
|
Arnie Wolfson
Manager, Business Development
Pharmaceutical Strategy Series
Cambridge Healthtech Institute
T: 781.972.5431
E: awolfson@healthtech.com
|
|
|
Other Series:
Proteomics, Drug Development,
Informatics,
Genomics,
Chemistry,
Diagnostic
|
|
|
|
|
|
Richard M. Bayney, Ph.D.
Vice President, Decision Analysis and Portfolio, Management, PRD
Johnson & Johnson
Balu Balasubramanian, Ph.D.,
Executive Director, Research and Development, Bristol-Myers Squibb Co.
Matt Bell, Ph.D., MA
Senior Director, Discovery Research Strategy, Wyeth
Dennis Engers
International Director, Preclinical Planning and Resource Management, sanofi-aventis
Rainer Fuchs, Ph.D.
Co-Head Discovery Research
Vice President, Research Informatics,
Biogen Idec Inc.
Richard Heaslip, Ph.D.
Vice President, Project and Portfolio Management,
Wyeth
Shama Kajiji, Ph.D., MBA
Director, Portfolio Franchise Management
Department,
Merck and Co
Sundeep Lal, Ph.D., MBA
Senior Director, New Products Licensing, Global
Human Health,
Merck & Co.
Michael Liebman, Ph.D.
Chief Scientific Officer,
Windber Research Institute
Jann Nielsen, Ph.D.
Director, Project Management,
Wyeth Research
James Resch, Ph.D.
Director, Strategic Planning, Global Discovery Affairs,
AstraZeneca
Jill Robinson, R.Ph., MBA
Vice President, Global Safety Surveillance & Epidemiology, Wyeth
Kim Slocum
Director, Strategic Planning & Business Development,
AstraZeneca LP
Sean Zhao, Ph.D.
Director, Pharmacovigilance and Global Safety, Amgen Inc.
|
|
 |
|
|
 |
|
|
 |
|
|
 |
|
|
|
|
|
